We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+35.14%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.02B
AUM Growth
+$319M
(+19%)
Cap. Flow
-$99.3M
Cap. Flow
% of AUM
-4.91%
Top 10 Holdings %
Top 10 Hldgs %
71.4%
Holding
52
New
6
Increased
25
Reduced
3
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
THOR
THORATEC CORPORATION
THOR
|
+$86.6M |
| 2 |
ENDP
Endo International plc
ENDP
|
+$71.9M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$36.8M |
| 4 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$31.3M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$27.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$169M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$131M |
| 3 |
CYBX
CYBERONICS INC
CYBX
|
+$72.8M |
| 4 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$42.6M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$10.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$22.7B
| $247M | 12.19% |
1,429,928
+26,800
| +2% | +$4.09M |
|
|
2
BioMarin Pharmaceuticals
BMRN
$13.3B
| $206M | 10.16% |
1,649,792
+347,595
| +27% | +$36.8M |
|
|
ANAC
3
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $189M | 9.32% |
3,259,045
+737,223
| +29% | +$31.3M |
|
|
ABMD
4
DELISTED
Abiomed Inc
ABMD
| $177M | 8.75% |
2,473,624
+13,500
| +0.5% | +$733K |
|
|
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
| $158M | 7.79% |
2,121,857
+19,000
| +0.9% | +$1.34M |
|
|
AMAG
6
DELISTED
AMAG Pharmaceuticals
AMAG
| $120M | 5.91% |
2,187,041
+192,841
| +10% | +$9.19M |
|
|
THOR
7
DELISTED
THORATEC CORPORATION
THOR
| $106M | 5.26% |
2,538,203
+2,269,342
| +844% | +$86.6M |
|
8
Insmed
INSM
$29.3B
| $96.7M | 4.78% |
4,649,448
+23,800
| +0.5% | +$419K |
|
|
ENDP
9
DELISTED
Endo International plc
ENDP
| $77.2M | 3.81% |
+860,204
| New | +$71.9M |
|
|
KYTH
10
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| $69.3M | 3.43% |
1,382,722
+260,838
| +23% | +$10.9M |
|
|
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
| $52.9M | 2.61% |
2,049,251
+9,500
| +0.5% | +$245K |
|
|
SQNM
12
DELISTED
SEQUENOM INC NEW
SQNM
| $39.4M | 1.95% |
9,977,642
+51,900
| +0.5% | +$191K |
|
13
Vanda Pharmaceuticals
VNDA
$297M
| $35.4M | 1.75% |
3,803,408
+16,500
| +0.4% | +$186K |
|
|
14
Karyopharm Therapeutics
KPTI
$44.6M
| $29.1M | 1.44% |
+63,402
| New | +$27.3M |
|
|
CELG
15
DELISTED
Celgene Corp
CELG
| $28.8M | 1.42% |
249,400
+33,900
| +16% | +$4.05M |
|
16
Gilead Sciences
GILD
$165B
| $28.6M | 1.41% |
291,000
+56,400
| +24% | +$5.73M |
|
|
EIGR
17
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $27.4M | 1.35% |
3,211
+91
| +3% | +$796K |
|
|
CYBX
18
DELISTED
CYBERONICS INC
CYBX
| $26.7M | 1.32% |
412,000
-1,196,101
| -74% | -$72.8M |
|
19
Prothena Corp
PRTA
$469M
| $26.5M | 1.31% |
695,918
+4,700
| +0.7% | +$121K |
|
|
SHPG
20
DELISTED
Shire pic
SHPG
| $22.7M | 1.12% |
95,000
+9,400
| +11% | +$2.16M |
|
|
MDVN
21
DELISTED
MEDIVATION, INC.
MDVN
| $22.2M | 1.1% |
343,400
+20,800
| +6% | +$1.19M |
|
|
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $22.1M | 1.09% |
1,455,176
| – | – |
|
|
HTWR
23
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $21.4M | 1.06% |
+243,868
| New | +$20.7M |
|
|
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
| $21.3M | 1.05% |
1,956,376
| – | – |
|
25
STAAR Surgical
STAA
$1.24B
| $19.6M | 0.97% |
2,642,922
+13,300
| +0.5% | +$97.3K |
|
Similar funds
RRA
AG
BL
CG
SCM
GAMA
PIM
ACA
Palo Alto Investors's Q1 2015 Portfolio in Review
As of Q1 2015, Palo Alto Investors held 52 positions worth $2.02B, up 19% from $1.7B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Palo Alto Investors withdrew a net $99.3M in Q1 2015, closing 6 positions and reducing 3 holdings. Its most notable exit was AUXILIUM PHARAMCEUTICALS INC, an estimated $169M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 58% a quarter earlier.
Against the trend, Palo Alto Investors opened a new position in Endo International plc worth $77.2M.
- Palo Alto Investors's largest Q1 2015 buy was Endo International plc: 860,204 shares worth $77.2M.
- Palo Alto Investors added most to THORATEC CORPORATION in Q1 2015, an estimated $86.6M increase.
- Palo Alto Investors's biggest Q1 2015 reduction was CYBERONICS INC, cutting an estimated $72.8M.
- Palo Alto Investors fully exited AUXILIUM PHARAMCEUTICALS INC in Q1 2015, selling an estimated $169M.
- Palo Alto Investors's ten largest holdings make up 71% of its $2.02B portfolio in Q1 2015.
- Palo Alto Investors opened 6 new positions and closed 6 in Q1 2015.
- Palo Alto Investors's portfolio value rose 19% quarter-over-quarter to $2.02B.
Based on Palo Alto Investors's 13F filing for Q1 2015, filed 15 May 2015.